Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Unlabelled: Polymyositis (PM) is usually associated to other autoimmune or connective tissue diseases. The authors report the case of a 59-year-old man with pulmonary fibrosis, who presented with constitutional symptoms and gradually developed proximal muscle weakness, Raynaud phenomenon, and dysphagia. Besides creatine kinase (CK) elevation, he had positive anti-Polymyositis-Scleromyositis (PM-Scl) and anti-Sjögren's-syndrome A (SSA) antibodies. Nailfold capillaroscopy showed a scleroderma pattern and muscle biopsy revealed necrosis, regeneration of muscle fibers, and inflammatory infiltrate. Prednisolone was started, with great improvement. Taking into account the overlap features between PM and systemic sclerosis sine scleroderma, it is important to closely monitor the patient for signs of pulmonary and cardiac decompensation.
Learning Points: Polymyositis (PM) may be associated with connective tissue diseases such as systemic sclerosis, including its variant without skin involvement.Necrotizing muscle fibers are typically found in patients with overlap syndrome, in opposition to patients only with polymyositis.PM-Scl antibodies are associated to a good response to corticoids.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346825 | PMC |
| http://dx.doi.org/10.12890/2015_000346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term oral glucocorticoid use is associated with complications, healthcare resource utilization, and costs among patients with dermatomyositis or polymyositis.
Clin Rheumatol
September 2025
Immunology Market Access, Johnson & Johnson, Horsham, PA, USA.
Introduction/objective: Oral glucocorticoids (OGC) are conventionally used as first-line treatment for dermatomyositis (DM) and polymyositis (PM). This study evaluated clinical and economic outcomes associated with long-term (LT) OGC use in DM/PM.
Methods: Adults with ≥ 2 medical claims of DM/PM 30‒365 days apart from January 1, 2016, to December 31, 2022, and ≥ 1 diagnosis code of a physician specialty of interest were selected from the MarketScan Commercial and Medicare Supplemental databases.
Diagnostic efficacy of serum Krebs von den Lungen-6 for dermatomyositis/polymyositis-associated interstitial lung diseases: A systematic review and meta-analysis.
Medicine (Baltimore)
September 2025
Academic Research Center, Yichang Hubo Medical Research Institute, Yichang City, Hubei Province, China.
Background: Previous studies have reported inconsistent findings regarding the diagnostic role of Krebs Von den Lungen-6 (KL-6) in dermatomyositis/polymyositis-associated interstitial lung disease (PM/DM-ILD) and its correlation with disease severity. This meta-analysis aimed to evaluate the diagnostic efficacy of serum KL-6 in detecting DM/PM-ILD and its association with pulmonary function.
Methods: In April 2023, we systematically searched PubMed, Web of Science, Cochrane Library, CNKI, Wan Fang, and VIP databases to identify studies investigating the association of KL-6 with DM/PM-ILD.
Case report: atypical anti-SAE1 autoantibody manifestation with splinter hemorrhages as onset, and related to urothelial cancer.
Eur Rev Med Pharmacol Sci
August 2025
SC Internal Medicine, University Hospital "SS. Antonio e Biagio e Cesare Arrigo", Alessandria, Italy.
Unlabelled: BACKGROUND: Subungual splinter hemorrhages may represent an expression of infective endocarditis as well as autoimmune diseases or neoplasms. Anti-SAE1 autoantibody is directed against a small ubiquitin-like modifier-activating enzyme that plays a role in regulating transcription, cell cycle, and apoptosis. It is specific for dermatomyositis with skin rash and mild muscle involvement, and it can be associated with cancer.
View Article and Find Full Text PDFA possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era.
Front Immunol
September 2025
Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, United States.
Introduction: Vaccinations have had a transformative impact on public health, reducing the incidence of many infectious diseases and increasing survival. However, there remains uncertainty about the potential of vaccines to trigger autoimmune diseases such as the idiopathic inflammatory myopathies (IIM). Myositis after vaccination (MAV) is a rare clinical entity, but given immunogenetic associations with other adverse events, we explored genetic risk factors, particularly human leukocyte antigen (HLA) alleles and GM/KM immunoglobulin allotypes, that may predispose individuals to develop MAV.
View Article and Find Full Text PDFRecurrence of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Following Long-Term Remission: A Report of Two Cases and Review of Literature.
Cureus
July 2025
Division of Rheumatology, Department of Medicine, Jichi Medical University Saitama Medical Center, Saitama, JPN.
We report two cases of anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) that recurred after long-term remission. The first case involved a 41-year-old Japanese woman, and the other involved a 31-year-old Chinese woman. Both patients were initially treated with prednisolone, tacrolimus, and low-dose intravenous cyclophosphamide.
View Article and Find Full Text PDF